Inventiva (IVA) Capital Expenditures (2019 - 2025)
Inventiva (IVA) recorded quarterly Capital Expenditures of -$64521.7 in Q2 2025, up 76.5% quarter-over-quarter from -$274606.3 in Q2 2024, and up 76.5% on a YoY basis from -$36555.4 in Q2 2024.
Inventiva (IVA) Capital Expenditures (2019 - 2025) Analysis & Trends
Inventiva's Capital Expenditures history runs 5 years deep, the most recent figure standing at -$64521.7 for Q2 2025.
- In Q2 2025, Capital Expenditures rose 76.5% year-over-year to -$64521.7; the TTM figure through Jun 2025 stood at -$949979.4 (up 10.9% YoY), while the FY2025 annual figure was $287518.7, down 19.2% from the prior year.
- Capital Expenditures was -$64521.7 for Q2 2025 at Inventiva, up from -$274606.3 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of -$49455.7 in Q1 2021 to a low of -$308858.1 in Q3 2022.
- Historically, Capital Expenditures has averaged -$188726.0 across 4 years, with a median of -$180747.4 in 2021.
- The sharpest annual moves came in 2022 and 2025: Capital Expenditures sank 67.08% in 2022, then soared 76.5% in 2025.
- A 4-year view of Capital Expenditures shows it stood at -$180747.4 in 2021, then tumbled by 67.08% to -$301993.2 in 2022, then increased by 9.07% to -$274606.3 in 2024, then jumped by 76.5% to -$64521.7 in 2025.
- The last three Capital Expenditures figures came in at -$64521.7 (Q2 2025), -$274606.3 (Q2 2024), and -$301993.2 (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -63,220.27 |
| 10 | Inventiva | 8.93 Mn | -259.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -64,521.70 |
| Jun 30, 2025 | -64,521.70 |
| Jun 30, 2024 | -274,606.33 |
| Jun 30, 2024 | -274,606.33 |
| Dec 31, 2022 | -301,993.22 |
| Dec 31, 2022 | -301,993.22 |
| Sep 22, 2022 | -308,858.12 |
| Sep 22, 2022 | -308,858.12 |
| Dec 31, 2021 | -180,747.41 |
| Dec 31, 2021 | -180,747.41 |
| Jun 30, 2021 | -140,899.76 |
| Jun 30, 2021 | -140,899.76 |
| Mar 31, 2021 | -49,455.68 |
| Mar 31, 2021 | -49,455.68 |
| Dec 31, 2019 | -161,605.60 |
| Dec 31, 2019 | -161,605.60 |